Medpace Holdings, Inc. reports developments in its global, full-service clinical contract research organization business, providing Phase I-IV clinical development services to biotechnology, pharmaceutical and medical device companies. Company news centers on quarterly and annual operating results, conference-call announcements and performance measures used in the CRO model, including revenue, EBITDA, backlog conversion, net new business awards and book-to-bill ratios.
Updates also describe Medpace's therapeutic and regulatory expertise across major development areas such as oncology, cardiology, metabolic disease, endocrinology, central nervous system, and anti-viral and anti-infective programs.
Medpace Holdings will announce its Q2 2024 financial results post-market on July 22, 2024.
A conference call to discuss the results is scheduled for July 23, 2024, at 9:00 a.m. ET.
Participants must register in advance via a provided link, and step-by-step access details will be sent by email.
The call can also be accessed through a webcast on Medpace's investor site, where a replay and supplemental slide presentation will be available post-call.
Medpace is traded under the ticker MEDP on Nasdaq.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Medpace Holdings, Inc. (Nasdaq: MEDP) reported robust financial results for Q1 2023, with revenue of $434.1 million, up 31.2% year-over-year. The company achieved a net book-to-bill ratio of 1.28x, with net new business awards of $555.8 million, a 31.4% increase. GAAP net income rose to $72.9 million or $2.27 per diluted share, compared to $61.3 million or $1.69 per diluted share last year. EBITDA increased 31.9% to $92.8 million, yielding an EBITDA margin of 21.4%. The company projects 2023 revenue between $1.745 billion and $1.805 billion, reflecting growth of 19.5% to 23.6%.
Cash flow from operations reached $80.1 million, with a remaining $332.7 million for share repurchase. Medpace will host a conference call on April 25, 2023, to further discuss these results.